Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma

Participants will undergo a CT or ultrasound guided biopsy of an accessible tumor lesion before beginning the study medication.
Everolimus tablets will be taken orally once a day. Participants will undergo a physical exam and will be asked questions about their general health and specific questions about any problems they might be having. Photographs will be taken of the tumor to assess the response to treatment. This will be done by a CT or MRI scan. Blood tests will be performed every 4 weeks. In addition, blood for research purposes will be done on day 1 of every other cycle. A urine test will be done every 4 weeks.